Business Description
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
ISIN : CNE100001R58
Share Class Description:
SZSE:300357: Class ACompare
Compare
Traded in other countries / regions
300357.China IPO Date
2014-01-21Description
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd is a Chinese bio-pharmaceutical company. It is engaged in the research development, production and sales of allergic diseases diagnosis and treatment products. The product portfolio of the company covers dust mites drops, dust mites skin prick diagnosis kit, silk, and others.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 16.9 | |||||
| Equity-to-Asset | 0.86 | |||||
| Debt-to-Equity | 0.03 | |||||
| Debt-to-EBITDA | 0.21 | |||||
| Interest Coverage | 242.49 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 32.25 | |||||
| Beneish M-Score | -2.73 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 10.1 | |||||
| 3-Year EBITDA Growth Rate | 7.6 | |||||
| 3-Year EPS without NRI Growth Rate | 4.5 | |||||
| 3-Year FCF Growth Rate | -2.4 | |||||
| 3-Year Book Growth Rate | 14.5 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 61.48 | |||||
| 9-Day RSI | 52.88 | |||||
| 14-Day RSI | 49.24 | |||||
| 6-1 Month Momentum % | -10.51 | |||||
| 12-1 Month Momentum % | -45.84 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 9.85 | |||||
| Quick Ratio | 9.48 | |||||
| Cash Ratio | 7.92 | |||||
| Days Inventory | 495.63 | |||||
| Days Sales Outstanding | 72.38 | |||||
| Days Payable | 62.43 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.9 | |||||
| Dividend Payout Ratio | 0.33 | |||||
| 3-Year Dividend Growth Rate | 3.6 | |||||
| Forward Dividend Yield % | 0.9 | |||||
| 5-Year Yield-on-Cost % | 1.12 | |||||
| Shareholder Yield % | 0.56 |
Profitability Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 95.35 | |||||
| Operating Margin % | 37.39 | |||||
| Net Margin % | 35.96 | |||||
| FCF Margin % | 18.5 | |||||
| ROE % | 14.85 | |||||
| ROA % | 12.78 | |||||
| ROIC % | 24.9 | |||||
| ROC (Joel Greenblatt) % | 47.31 | |||||
| ROCE % | 15.57 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 37.74 | |||||
| PE Ratio without NRI | 37.67 | |||||
| Shiller PE Ratio | 47.56 | |||||
| Price-to-Owner-Earnings | 57.37 | |||||
| PEG Ratio | 4.14 | |||||
| PS Ratio | 13.62 | |||||
| PB Ratio | 5.27 | |||||
| Price-to-Tangible-Book | 5.74 | |||||
| Price-to-Free-Cash-Flow | 73.48 | |||||
| Price-to-Operating-Cash-Flow | 35.04 | |||||
| EV-to-EBIT | 29.05 | |||||
| EV-to-EBITDA | 29.05 | |||||
| EV-to-Revenue | 11.88 | |||||
| EV-to-FCF | 65.62 | |||||
| Price-to-Projected-FCF | 3.03 | |||||
| Price-to-DCF (Earnings Based) | 1.57 | |||||
| Price-to-DCF (FCF Based) | 3.25 | |||||
| Price-to-Median-PS-Value | 0.52 | |||||
| Price-to-Peter-Lynch-Fair-Value | 5.59 | |||||
| Price-to-Graham-Number | 3.12 | |||||
| Price-to-Net-Current-Asset-Value | 9.7 | |||||
| Price-to-Net-Cash | 12.99 | |||||
| Earnings Yield (Greenblatt) % | 3.44 | |||||
| FCF Yield % | 1.36 | |||||
| Forward Rate of Return (Yacktman) % | 8.2 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers